A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
The purpose of this study is to look at the effects of different methods of birth control
(oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV).
This study will also evaluate the differences in men and women in how the body absorbs, makes
available, and removes ZDV.
Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased
in individuals who use certain methods of birth control. ZDV may also have different effects
in men compared to women.
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
Completed
Baylor College of Medicine
Phase 2
1993-01-01
OBJECTIVES:
I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and
leuprolide/oral contraceptive therapy in the management of patients with ovarian
hyperandrogenism.
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
Completed
National Center for Research Resources (NCRR)
Phase 2
1993-01-01
OBJECTIVES:
I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and
leuprolide/oral contraceptive therapy in the management of patients with ovarian
hyperandrogenism.
Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus
Completed
University of Alabama at Birmingham
N/A
2000-06-01
OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic
estrogens and progestins on disease activity in premenopausal women with inactive, stable, or
moderate systemic lupus erythematosus (SLE).
II. Determine the effect of hormone replacement therapy with conjugated estrogens and
progestins on disease activity in postmenopausal women with inactive, stable, or moderate
SLE.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
